CLL-Lymphoma
US Focus Meeting 2026
📍 Estancia La Jolla Hotel, 9700 N Torrey Pines Rd, La Jolla, CA 92037
🗓️ May 8 - 9, 2026
Last Year's Highlights
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the CLL-Lymphoma Focus Meeting 2026, to be held at on May 8 - 9, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing CLL-Lymphoma research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of CLL-Lymphoma US Focus Meeting 2026:
Susan O’Brien, MD
University of California, Irvine Medical Center, Los Angeles, CA
Christopher Flowers, MD
MD Anderson Cancer Center, Houston, TX
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
neve.rowlands@md-education.com
Agenda & Faculty
May 8, 2026 | CLL Day
Session I
Moderated by:
TBD
KOL TBD
KOL TBD
09:00 PM
Proteomics in CLL
Catherine Wu, MD
Dana-Farber Cancer Institute, Boston, MA
09:20 PM
How I Choose Frontline Therapy for Which Patient
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
09:40 PM
Where Does Pirtobrutinib Fit in Now?
JR
Joanna Rhodes, MD
Rutgers Cancer Institute, New Brunswick, NJ
Session II
Moderated by:
TBD
KOL TBD
KOL TBD
10:50 AM
CAR-T in CLL
David Maloney, MD
Fred Hutchinson Cancer Research Center, Seattle, WA
11:10 AM
BTKI + BCL2i Combinations in CLL
Mazyar Shadman, MD
Fred Hutchinson Cancer Research Center, Seattle, WA
11:30 AM
Survivorship in CLL
Alessandra Ferrajoli, MD
MD Anderson Cancer Center, Houston, TX
Session III
Moderated by:
TBD
KOL TBD
KOL TBD
01:55 PM
Treatment of Patients with P53 Aberrations
Nicole Lamanna, MD
The Herbert Irving Comprehensive Cancer Center, New York, NY
02:15 PM
Update on Richters
MT
Meghan Thompson, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
02:35 PM
Is the Use of MRD Standard of Care in CLL?
Carolyn Owen, MD
University of Calgary, Canada
Session IV
Moderated by:
TBD
KOL TBD
KOL TBD
04:30 PM
BTK Degraders
Matthew Davids, MD
Dana-Farber Cancer Institute, Boston, MA
04:50 PM
Bispecifics in CLL
Bita Fakhri, MD
Stanford Medicine, CA
05:10 PM
Future Questions in CLL
Jennifer Brown, MD
Dana-Farber Cancer Institute, Boston, MA
May 9, 2026 | Lymphoma Day
Session I: Biomarkers, MRD Precision Tools in Lymphoma
Moderated by:
Laurie Sehn, MD
BC Cancer Agency, Vancouver, Canada
09:05 AM
Cell-Free DNA in Lymphoma: From Detection to Decision-Making
Ash Alizadeh, MD
Stanford Medicine, CA
09:25 AM
MRD and Risk-Adapted Approaches in LBCL and FL
Jordan S. Goldstein, MD
Stanford Medicine, CA
09:45 AM
Genetic Subtype-Guided Trials Clinical Application in 2026
David Scott, MD
BC Cancer Agency, Vancouver, Canada
Session II: Frontline and Relapsed LBCL - State of the Art
Moderated by:
TBD
KOL TBD
KOL TBD
10:55 AM
Tailoring First-Line Therapy in LBCL: Pola-R-CHP and Beyond
Laurie Sehn, MD
BC Cancer Agency, Vancouver, Canada
11:15 AM
Innovative Strategies in Relapsed/ Refractory DLBCL
Dai Chihara, MD
MD Anderson Cancer Center, Houston, TX
11:35 AM
Bispecific Abs in First and Second Line Therapy for DLBCL
Elizabeth Budde, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
Session III: Clinical Trial Design & Regulatory Innovation
Moderated by:
TBD
KOL TBD
KOL TBD
02:00 PM
Using Real-World Evidence (RWE) in Lymphoma Drug Development
Christopher Flowers, MD
MD Anderson Cancer Center, Houston, TX
02:20 PM
Biomarker Driven Trials: Smarter Endpoints, Learner Designs
Michael R. Green, PhD
MD Anderson Cancer Center, Houston, TX
02:40 PM
Clinician's View: What Makes a Trial Practically Useful?
KM
Kami J. Maddocks, MD
The Ohio State University, Comprehensive Cancer Center, Columbus, OH
Session IV: TBD
Moderated by:
Pamela Allen, MD
Winship Cancer Institute of Emory University, Georgia
04:35 PM
Novel Targets in PTCL: Clinical Update
LC
Luis Malpica Castillo, MD
MD Anderson Cancer Center, Houston, TX
04:55 PM
Cutaneous T-Cell Lymphoma: Emerging Therapies and Trials
Pamela Allen, MD
Winship Cancer Institute of Emory University, Georgia
05:15 PM
CNS Lymphoma: What's New in Targeted Approaches?
Ayushi Chauhan, MD
Wellstar MCG Health, Georgia
Neve Rowlands
Project Manager
How long has Neve Rowlands been in the business?
Neve Rowlands has been with MD Education since 2023.
About Neve Rowlands
I am a dedicated project manager in the hematology industry, with a current focus on CLL and lymphoma. Specialising in logistical organisation with a sharp eye for detail, and committed to delivering high-quality, seamless events. The most rewarding part of the role is watching meetings come to life. I am passionate about connecting with both familiar and new faces, and driven by the impact of well-executed projects that support meaningful progress in the field.
